Main Article Content

Abstract

b-thalassemia major is a genetic disease and a decline in production due to imperfect of hemoglobin. Clinical manifestations are anemia, treated with regular blood transfusions. Blood transfusions lead to an increase in iron in the body that can lead to organ complications. Iron chelation drug delivery is expected to reduce complications due to an increase in the amount of iron in the body by measuring serum ferritin. The study aims to analyze the use of deferasirox and deferipron in patients with b-thalassemia major children at Dr. Kariadi Hospital of January 1, 2012 until December 31, 2013 as well as the need for blood transfusions. Patients who met the inclusion criteria, ie patients with b-thalassemia major children, retrospectively conducted observations of medical records include basic data and laboratory data. After descriptive analysis was performed to determine the use of two types of iron chelating drugs. In this study, 9 patients included in the inclusion criteria. A total of 5 people using deferasirox and 4 using deferipron at baseline. There are 3 people who turned deferipron be deferasirox. Serum ferritin values at study entry was> 1200 mcg/L, and at the end of the study serum ferritin is> 1200 mcg/L. The mean dose of deferasirox study was 19 ± 4.3 mg, and the dose deferipron mean was 80.8 ± 7.7 mg. Mean hemoglobin levels before transfusion was 6.60 ± 0.89 mg/dL. The average number of blood transfusions given was 336.52 ± 73.85 ml. Type of blood transfusion is used Washed erythrocyte. Splenomegaly occurred in 2 patients. There is no change in renal function, and hepatic meaning. The final conclusion until the reduction target serum ferritin <1000 mg/L has not been reached. Deferasirox dose can be increased to achieve the expected serum ferritin.

Keywords

-thalassemia mayor childern deferasirox deferipron

Article Details

How to Cite
Sutrisnaningsih, E. S., Suharjono, S., & Sudarmanto, B. (2017). ANALYSIS OF DEFERASIROX AND DEFERIPRON USE IN CHILDREN WITH PEDIATRIC -THALASSEMIA MAJOR. Folia Medica Indonesiana, 52(1), 42–46. https://doi.org/10.20473/fmi.v52i1.5207

References

  1. Agarwal MB (2009). Advances in management thalas-semia. Indian Journal of Pediatrics 76, 177-184
  2. Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, Zimmermann A, Manz C (2007). A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica 92, 1599-1606
  3. Ganie RA (2005). Thalassemia: permasalahan dan penanganannya. Pidato Pengukuhan Jabatan Guru Besar Tetap dalam Bidang Ilmu Patologi pada Fakultas Kedokteran, Universitas Sumatera Utara, Presented in Medan November 16, 2005
  4. Olivieri NF and Weatherall DJ (2006). Thalassemias. In: Arceci RJ, Hann IM, Smith OP, Hoffbrand AV (eds). Pediatric Hematology 3rd Ed, Massachusetts, Blackwell Publishing, p 281-305
  5. Priyatinigsih DR (2010). Pengaruh deferasirox terhadap kadar T4 dan TSH pada penderita ï¢-Thalassemia Mayor dengan feritin yang tinggi. Thesis. Universitas Diponegoro, Semarang
  6. Ruswandi (2009). Jumlah penderita thalassemia naik 8,3%. Available from http://kesehatan.kompas.com/ read/2009/03/05/21122544/Jumlah.Penderita.Thalassemia.Naik.8.3.Persen. Accessed March 5, 2009
  7. Turgeon ML (2011). Clinical Hematology Theory and Procedures 5th ed, Philadephia, Lippincott Williams & Wilkins, p 220-223
  8. Won SC, Han DK, Seo JJ, Chung NG, Park SK, Park KB, Kook H, Lyu CJ (2010). Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients. Korean J Hematol 45, 58-61

Most read articles by the same author(s)